Clinical Trial Update: Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Nimotuzumab plus Paclitaxel and Cisplatin as first-line treatment for esophageal squamous cell carcinoma. The trial statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nimotuzumab (nimotuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Peking University | Conditions: Esophageal Squamous Cell Cancer | Phase 2 | Status: UNKNOWN